EQ NASDAQ
Equillium, Inc.
1W: -1.4%
1M: -19.1%
3M: -40.4%
YTD: -11.1%
1Y: -3.5%
3Y: +130.5%
5Y: -76.2%
$1.36
+0.11 (+8.80%)
Weekly Expected Move ±13.3%
$1
$1
$1
$1
$2
Credit Risk of going bust: higher than 56% of companies Debt: 0.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down 99.8%), Equillium, Inc. would be worth roughly what it owes.
Total debt $584K against a stock market value of $86.2M.
Distance to default 4.53 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $498K (short-term plus half of long-term), stock volatility 103.7%; Altman Z'' 13.72. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down 99.8%), Equillium, Inc. would be worth roughly what it owes.
Total debt $584K against a stock market value of $86.2M.
Distance to default 4.53 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $498K (short-term plus half of long-term), stock volatility 103.7%; Altman Z'' 13.72. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (30)
Equillium, Inc. (NASDAQ:EQ) Stock Has Average Target Price of $7.57 According to Brokerages
Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504
Equillium, Inc. (NASDAQ:EQ) Receives $7.57 Average Target Price from Analysts
Equillium, Inc. (NASDAQ:EQ) Given Consensus Recommendation of “Moderate Buy” by Analysts
Analysts Set Equillium, Inc. (NASDAQ:EQ) PT at $7.57
Which companies reporting earnings this week show the strongest bullish signals?
Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis
12 Health Care Stocks Moving In Friday's After-Market Session
Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights
Equillium to Participate in Oppenheimer's 2026 Innovation on the Island Event
12 Health Care Stocks Moving In Monday's After-Market Session
Analysts Set Equillium, Inc. (NASDAQ:EQ) Target Price at $9.00
Aberdeen Group plc Grows Stake in Equillium, Inc. $EQ
Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists
Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists
Equillium GAAP EPS of -$0.04 beats by $0.02, revenue of $0M
Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights
Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights
3 things to look forward to on Monday
Equillium to Participate in the 38th Annual Roth Conference
Christine Zedelmayer Sells 120,312 Shares of Equillium (NASDAQ:EQ) Stock
Cantor Fitzgerald L. P. Invests $608,000 in Equillium, Inc. $EQ
Analysts Set Equillium, Inc. (NASDAQ:EQ) Target Price at $6.00
Equillium stock jumps on $35M financing from RA Capital Management
Equillium Announces $35 Million Financing with RA Capital Management
Equillium: Multi-Cytokine Platform To Go Beyond Scope Of EQ504 For UC
Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference
Short Interest in Equillium, Inc. (NASDAQ:EQ) Increases By 32.2%
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Equillium to Participate in Upcoming Investor Conferences